Try

Esperion Therapeutics, Inc.

ESPRUnited States

44 filed reports · 380 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$403MFY2025 · to Dec 31, 2025+21.3% from $332M10-K$80.1MQ1 FY2026 · to Mar 31, 2026+23.2% from $65M10-Q
Net income-$22.7MFY2025 · to Dec 31, 2025a year earlier: -$51.7M10-K-$25.2MQ1 FY2026 · to Mar 31, 2026a year earlier: -$40.5M10-Q
Operating income$60.3MFY2025 · to Dec 31, 2025+10.8% from $54.4M10-K-$6.58MQ1 FY2026 · to Mar 31, 2026a year earlier: -$22.1M10-Q

Filed reports

44 reports · Jun 2015 to Mar 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR333,643Jun 2015 to Mar 2026
Annual · 10-KSEC EDGAR113,627Dec 2015 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q110-QMar 31, 2026May 8, 2026282Open
FY202510-KDec 31, 2025Mar 10, 2026661Open
FY2025 Q310-QSep 30, 2025Nov 6, 2025183Open
FY2025 Q210-QJun 30, 2025Aug 13, 2025151Open
FY2025 Q110-QMar 31, 2025May 8, 2025136Open
FY202410-KDec 31, 2024Mar 7, 2025336Open
FY2024 Q310-QSep 30, 2024Nov 7, 2024129Open
FY2024 Q210-QJun 30, 2024Aug 12, 2024116Open
FY2024 Q110-QMar 31, 2024May 7, 2024129Open
FY202310-KDec 31, 2023Feb 27, 2024212Open
FY2023 Q310-QSep 30, 2023Nov 7, 2023137Open
FY2023 Q210-QJun 30, 2023Aug 1, 2023114Open

Financial data

380 concepts · 7,270 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial379 concepts · 7,167 facts · Dec 2013 to Mar 2026

  • Cash and cash equivalents at carrying value62 · Dec 2013 to Mar 2026
  • Comprehensive income net of tax62 · Dec 2013 to Mar 2026
  • Income tax expense benefit62 · Dec 2013 to Mar 2026
  • Net income loss62 · Dec 2013 to Mar 2026
  • Operating expenses (US GAAP)62 · Dec 2013 to Mar 2026
  • Operating income loss62 · Dec 2013 to Mar 2026
  • Other nonoperating income expense62 · Dec 2013 to Mar 2026
  • Research and development expense excluding acquired in process cost62 · Dec 2013 to Mar 2026
  • Depreciation60 · Dec 2013 to Mar 2026
  • Increase decrease in other accrued liabilities60 · Dec 2013 to Mar 2026
  • Increase decrease in prepaid deferred expense and other assets60 · Dec 2013 to Mar 2026
  • Share based compensation60 · Dec 2013 to Mar 2026
  • Common stock par or stated value per share59 · Dec 2013 to Mar 2026
  • Stockholders equity (US GAAP)59 · Dec 2013 to Mar 2026
  • Increase decrease in accounts payable58 · Dec 2013 to Mar 2026
  • Accounts payable current57 · Dec 2014 to Mar 2026
  • Accrued Clinical Development Costs, Current57 · Dec 2014 to Mar 2026
  • Additional paid in capital57 · Dec 2014 to Mar 2026
  • Assets57 · Dec 2014 to Mar 2026
  • Assets current57 · Dec 2014 to Mar 2026
  • Common stock shares authorized57 · Dec 2014 to Mar 2026
  • Common stock shares issued57 · Dec 2014 to Mar 2026
  • Common stock value57 · Dec 2014 to Mar 2026
  • Liabilities57 · Dec 2014 to Mar 2026

Product1 concept · 103 facts · Dec 2018 to Mar 2026

  • Revenue103 · Dec 2018 to Mar 2026

Segments

103 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service8 members · 103 facts

  • Collaboration revenue37 · Dec 2018 to Mar 2026
  • Product sales, net35 · Dec 2018 to Mar 2026
  • Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received13 · Dec 2022 to Mar 2026
  • Ongoing regulatory and development activities6 · Mar 2019 to Dec 2020
  • License for the intellectual property5 · Mar 2019 to Dec 2019
  • Royalty Revenue From DSE And Sale Of Bulk Tablets3 · Dec 2021 to Dec 2023
  • Ongoing regulatory activities2 · Mar 2019 to Mar 2020
  • Royalty Revenue From DSE2 · Dec 2020 to Dec 2021

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Esperion Therapeutics, Inc. (ESPR) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.

Esperion Therapeutics, Inc. (ESPR): FY2025 revenue $403M · FactIQ